Sarawgi Devansi, Rudra Olympia
Dermatology, Institute of Post Graduate Medical Education & Research, Kolkata, IND.
Cureus. 2023 May 29;15(5):e39649. doi: 10.7759/cureus.39649. eCollection 2023 May.
Tadalafil is a phosphodiesterase-5 (PDE-5) inhibitor, an FDA-approved treatment for erectile dysfunction (ED), pulmonary arterial hypertension (PAH), benign prostate hyperplasia, etc. It is also widely used by otherwise healthy individuals for recreational purposes. Fixed drug eruption (FDE) is a distinctive type of adverse drug reaction in which every exposure to the offending medication leads to the appearance of lesions at the same 'fixed' sites. A sharply defined erythematous patch or plaque with a violaceous hue is typically seen. A clinical variant featuring classic FDE lesions along with blistering in at least three out of six anatomical sites or involving at least 10% of body surface area is known as generalized bullous fixed drug eruption (GBFDE). Tadalafil-induced FDE is in itself an uncommon phenomenon, with only a handful of documented cases, none of which seem to have reported GBFDE-type presentation post-tadalafil intake. Here, we present a case of GBFDE following tadalafil administration.
他达拉非是一种磷酸二酯酶-5（PDE-5）抑制剂，是一种经美国食品药品监督管理局（FDA）批准用于治疗勃起功能障碍（ED）、肺动脉高压（PAH）、良性前列腺增生等疾病的药物。它也被其他健康个体广泛用于娱乐目的。固定性药疹（FDE）是一种独特的药物不良反应类型，每次接触致病药物都会在相同的“固定”部位出现皮损。通常可见边界清晰的紫红色红斑或斑块。一种临床变体，其特征为具有典型的FDE皮损，同时在六个解剖部位中的至少三个部位出现水疱或累及至少10%的体表面积，被称为泛发性大疱性固定性药疹（GBFDE）。他达拉非引起的FDE本身是一种罕见现象，仅有少数病例记录，其中似乎没有报告在服用他达拉非后出现GBFDE型表现的情况。在此，我们报告一例服用他达拉非后出现GBFDE的病例。
